Ellen Baron

Dr. Ellen Baron has been a Managing Director of Outcome Capital LLC, a specialized life science and technology advisory and investment banking firm since February 2017. From 2012 to 2017, she served as a Managing Director of Healthios Capital Markets, LLC. Prior to joining Healthios, Dr. Baron served as Partner for Oxford Bioscience Partners, a life science and healthcare sector-focused venture capital fund, and as Senior Vice President, Business Development at Human Genome Sciences, a publicly-traded biopharmaceutical company. Dr. Baron previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a biotech company, Sixth Element Capital, a UK-based oncology-focused venture capital fund and SFH, a Maine-based nutraceutical company. Dr. Baron holds a Ph.D. in Microbiology from Georgetown University School of Medicine, a post-doctorate at the Public Health Research Institute in New York, and a B.S. from Goucher College.

Dr. Ellen Baron brings extensive experience in financing life science companies and has deep domain expertise across multiple disciplines in the pharmaceutical and biotechnology industries.